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INTRODUCTION 
Anemia define as a reduction in red blood cell mass, 
hemoglobin (Hb)<12g/dL and hematocrit less than 36% in 
women and Hb<14 g/dL and hematocrit less than 41% in 
men and its clinical manifestations vary according to 
etiology, severity and starting speed. Other disorders such 
as cardiopulmonary diseases may be effective in the 
severity of anemia symptoms. Severe anemia can be 
tolerated if it is gradually developed, but usually patients 
with Hb<7g/dL show hypoxic tissue symptoms such as 
fatigue, headache, asthma, light-headedness and angina. 
Wannes, visual disturbance, Syncop and tachycardia may 
be an indication of hypovolemic anemia that needs to 
immediate attention.1  
According to Prakash idea in 2012, anemia was common 
in the intensive care unit (ICU) and increases morbidity 
and mortality; its etiology is multi-factorial but anemia due 
to inflammation is the most important cause and is exactly 
like anemia of iron deficiency. Transfusion and the use of 
erythropoietin are two methods that are used to correct 
anemia in sick patients.2 A great part of these patients have 
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anemia during hospitalization and a great part of them 
undergoing anemia during their stay in the ICU that 
anemia increases with the duration of hospitalization in the 
ICU. Sekhon and et al, stated that the average of Hb on day 
seventh is less than 9 g /dL in hospitalized patients with 
severe brain trauma which admitted to ICU with high 
mortality risk.3 In various studies it has been shown that 
95% of patients suffered to anemia in the third day of 
hospitalization in ICU.4 This event may be due to the fact 
that patients with severe illness who need to be admitted to 
the ICU, in 90% of cases it has low of iron and total 
connection capacity (TIBC) and had normal or slightly 
higher than normal ferritin.5-6  
Herbert and et al in a study showed that the effect of 
maintaining Hb in ICU patients at 8-9g/dL is at least equal 
to the effect of maintaining this level at 10g/dL by helping 
transfusion. Also, transfusion to be widely used for anemia 
patients.7 50% of all anemia patients during their 
hospitalization in the ICU and 85% of patients with more 
than one week hospitalization in ICU undergoing blood 
transfusion at least once.8-9 Transfusion is not a safe 
process and can have many problems including infection, 
immune response, pulmonary edema and pulmonary 
injury to the recipient, especially when this person has 
other problems that led to his hospitalization in the 
ICU.10,11 Due to the dangers of transfusion, there is 
emergency need for alternative treatment for anemia in 
severe patients. Erythropoietin treatment in severe patients 
increases erythropoietin and results in high levels of 
hemoglobin and finally reduced transfusion.12-15 The aim 
of this study was to evaluate the efficacy of erythropoietin 
in the treatment of anemia in ICU patients in Ardabil. 
METHODS 
This is a clinical trial study conducted at ICU in Ardabil 
hospitals. A total of 70 patients hospitalized in the ICU 
were selected and randomly divided into two similar 
groups. To the first group in addition to iron, 
erythropoietin was also prescribed, and only iron was 
given to the second group (control group). 100mg iron was 
prescribed for all patients. For the case group in the state 
of a decrease in Hb levels less than 12g/dL for three times 
40,000 units of erythropoietin were injected weekly. In the 
case of hemoglobin less than 8mg/dL in non-cardiac 
patients and hemoglobin less than 10mg/dL in patients 
with heart disease (ischemic) blood were also prescribed 
for patients. At the end of study, blood indices and clinical 
status of the patient were evaluated at the end of the study. 
Required information including demographic information, 
cause and duration of hospitalization in ICU, history of 
transfusion, cause of need for blood transfusion, time and 
dose of receiving erythropoietin, blood parameters before 
and after receiving erythropoietin and patient's clinical 
condition after receiving erythropoietin was extracted 
through a checklist. Data were analyzed by statistical 
methods in SPSS version 19. In all tests the level of 
significance was less than 0.05.  
Inclusion and exclusion criteria 
Patients aged 18 years and above, Hematocrit less than 
38% and hospitalization in ICU for more than 7 days were 
enrolled in the study. Patients with uncontrolled 
hypertension, uncontrolled seizures, burn grade 3 and 
higher, pregnancy or lactation, dialysis patients, 
pulmonary embolism, DVT and chronic 
hypercoagulopathy were excluded from the study. The 
study was conducted after approval at the university’s 
ethics committee. 
RESULTS 
In this study, 65.7% of the case group and 71.4% of the 
control group were male and the rest of them were female. 
The mean age of the patients in the case group was 
61.62±20.8 and in the control group was 61.02±22.5 years 
(Table 1).  
Table 1: Clinical characteristics of patients in two 
study group. 
Control  Case  Groups 
Variables % n % n 
71.4 25 65.7 23 m 
sex 
28.6 10 34.3 12 f 
48.6 17 54.3 19 >70 
Age  
51.4 18 45.7 16 <=70 
61.02±22.5 61.62±20.8 Mean of age 
30.2±21.5 32.2±21.7 
Mean of 
hospitalization 
77.1 27 82.9 29 + 
RH+ 
22.9 8 17.1 6 - 
60 21 68.6 24 + History of 
heart disease 40 14 31.4 11 - 
42.9 15 40 14 + 
Blood type o 
57.1 20 60 21 - 
20 7 25.7 9 + History of 
transfusion 80 28 74.3 26 - 
88.6 31 80 28 + Need for 
transfusion 11.4 4 20 7 - 
The mean of injected blood in patients receiving blood in 
the case group was 5.8±1.8 and 6.3±2.9 in the control 
group.13 patients in the case group were between 3 to 6 
units and 15 patients in the control group received 7-9 
blood units. The most common cause of blood transfusion 
was acute anemia in both groups. In the case group, 24 
patients (68.6%) and in the control group, 25 patients 
(71.4%) survived until the ICU discharged and the end of 
the study. In term of complications of erythropoietin 
injection, we observed that none of the patients in the case 
group hadn’t complications. The results showed no 
significant difference in the experimental results of the 
patients at the beginning of the study (Table 2).  
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Table 2: The results of experimental finding in 
patients in baseline. 
Variables  Case Control 
p-
value 
Hb 
Case  78/10 92/1 
558/0 
Control  03/11 71/1 
Hematocrit 
Case  80/30 98/5 
444/0 
Control  86/31 50/5 
Platelet  
Case  315000 95000 
318/0 
Control  285000 84000 
Iron 
Case  3/52 5/32 
337/0 
Control  7/48 5/28 
Ferritin 
Case  5/668 5/317 
290/0 
Control  4/721 7/468 
BUN 
Case  65/66 04/43 
853/0 
Control  5/68 6/41 
Cr 
Case  54/1 12/1 
834/0 
Control  62/1 16/1 
The results showed that, there was no significant increase 
in hemoglobin and Hematocrit levels after receiving 
erythropoietin in the case group compare to control group 
(Table 3). Hemoglobin levels in the case group at the end 
of the study was significantly higher than the baseline but 
in the Hematocrit level the difference wasn’t significant 
(Table 4). 
Table 3: Hb and Hematocrit of patients after                         
drug receiving. 
Variables  Case Control 
p-
value 
Hb 
Case  95/11 50/1 
105/0 
Control  40/11 26/1 
Hematocrit 
Case  07/35 54/4 
074/0 
Control  25/33 79/3 
Table 4: Compare the Hb of patients in two groups in 
the end of study compare to base line. 
Variables  Case Control p-value 
Case  
Baseline 78/10 92/1 
006/0 End of 
study 
95/11 50/1 
Control  
Baseline 03/11 71/1 
307/0 End of 
study 
40/11 26/1 
DISCUSSION 
Anemia is a common problem in ICU patients who 
increase their illness and mortality.2 In this study, the mean 
of hospital stay was 37.73 days in ICU and 21.35 days in 
surgery ICU. Also, it was observed that hemoglobin level 
in internal patients at the beginning of the study was lower 
than surgical patients (P=0.023) and the increase in 
hemoglobin level in internal patients was significantly 
higher than patients undergoing surgery (P=0.001). In a 
study by Corwin et al 16 there was no significant 
correlation between the duration of hospitalization in ICU 
between traumatic and non traumatic patients after 
receiving erythropoietin (P=0.43). In Georgopoulos et al 
study13, the duration of hospitalization in ICU in the 
control group was 21.8 days and, in the group, receiving 
erythropoietin (once daily) was 21 days and in the recipient 
of erythropoietin (three times a day) was 19.6 days but this 
difference wasn’t significant. In the study of van Iperen 
and et al, the mean duration of hospitalization in ICU was 
37 days in erythropoietin recipients and 58 days in placebo 
and this difference was statistically significant (P=0.03).6 
In this study, 80% of patients in the case group and 88.57% 
in the control group needed to blood transfusion. The mean 
of need for transfusion in case group was 5.8±1.8 and in 
the control group was 3.6±2.9 and it was found that 
erythropoietin could not reduce the number of recipients 
and the number of P/C units. Studies done elsewhere is in 
line with the study results.6,17,18 There were also conflicting 
studies with our study and had adverse results.13,19,20  
The reason for the lack of correlation between the numbers 
of transfusions with erythropoietin injection in this study 
can be due to: 1) transfusion at higher levels of hemoglobin 
2) the most common cause of bleeding and acute anemia 
among patients and other factors. 
In this study, 68.6% of patients in the case group and 
71.4% of the patients in the control group survived to the 
end of the study and discharge from the ICU and there was 
no difference in the prognosis of the disease between the 
two groups. The present study showed that there is no 
correlation between the prognosis of patients admitted to 
ICU and erythropoietin administration which in line with 
our study results.12-14,19,20  
A number of studies have also shown that injectable 
erythropoietin could improve the prognosis of patients.19,21 
In the following study the prognosis of patients was 
different for different reasons and authors can’t said that 
erythropoietin can interfere with patient’s prognosis which 
most studies have confirmed. 
In this study, there was no significant difference in the 
level of hemoglobin between two groups at the time of 
admission and at the end of the study. It was observed that 
hemoglobin level was significantly increased in the 
erythropoietin recipient group (P=0.006) that this increase 
wasn’t observed in the control group. The results of this 
study are in line with other studies12-14,17,19,21  
In this study, no significant difference was found between 
the hemoglobin in the case and control groups which can 
be related to the more transfusion in these patients but in 
summary erythropoietin could be increase hemoglobin 
levels in recipients. 
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CONCLUSION 
The results of this study showed that erythropoietin is 
effective drug for increasing hemoglobin levels and can 
increase the hemoglobin level in compare to the placebo.  
It is suggested that another study has been done to evaluate 
the level of hemoglobin in patients with chronic 
underlying illness in the future in a larger population. 
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